Viewing Study NCT04930094


Ignite Creation Date: 2025-12-25 @ 1:43 AM
Ignite Modification Date: 2025-12-27 @ 12:53 PM
Study NCT ID: NCT04930094
Status: ACTIVE_NOT_RECRUITING
Last Update Posted: 2025-10-31
First Post: 2021-06-15
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Phase III Study of Efficacy and Safety of Secukinumab Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patients With Giant Cell Arteritis (GCA)
Sponsor: Novartis Pharmaceuticals
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module